The Multicenter Cardiology Monitoring Platform Registry

NCT04976348 | Recruiting DMC

• 1 other identifier: NL76585.068.21
• Study Type: observational
• Target: 40,000
• Locations: 1 country
• Sites: 1

Brief Summary

The multicenter Cardiology Monitoring Platform registry (mCMP-registry) is a prospective observational registry including multi-omics (diagnostic) measurements performed as part of routine clinical care, bio-banking (optional), and yearly questionnaires (optional). It's objective is to optimize (early) diagnosis and risk-stratification of (early) cardiovascular diseases, specifically cardiomyopathy phenotypes, arrhythmias, and coronary artery disease, and to create a better understanding of underlying pathophysiological processes.

Conditions

Heart Failure; Cardiomyopathies; Atrial Fibrillation; Ventricular Arrythmia; Coronary Artery Disease; Ventricular Tachycardia

Keywords

heart failure; registry; cardiomyopathy; atrial fibrillation; ventricular tachycardia; coronary artery disease

Outcome Measures

Primary Outcomes (1)

• (sudden) cardiac death or heart transplantation

  Death attributed to a cardiac cause or sudden, or heart transplantation.

  through study completion, an average of 15 years

Secondary Outcomes (4)

• Heart Failure hospitalization

  through study completion, an average of 15 years

• Life-threatening arrhythmias

  through study completion, an average of 15 years

• Quality of life EQ-5D questionnaire

  through study completion, an average of 15 years

• Economic burden

  through study completion, an average of 15 years

Other Outcomes (5)

• Age

  through study completion, an average of 15 years

• Sex

  through study completion, an average of 15 years

• Body mass index

  through study completion, an average of 15 years

Study Arms (1)

Consenting participants

All subjects aged ≥16 years referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines) or for cardiac/cardiogenetic screening.

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All subjects aged ≥16 years that have been referred to the cardiology or genetics department for cardiac symptoms, cardiac screening or cardiogenetic screening are eligible for inclusion.

You may qualify if:

• Referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines(3)) or for cardiac/cardiogenetic screening;
• Age ≥16 years.

You may not qualify if:

• Unwillingness to participate or unable to give written informed consent (e.g. due to language barriers or severe intellectual disability).

Sponsors & Collaborators

• Maastricht University Medical Center: lead
• Zuyderland Medical Centre: collaborator

Study Sites (1)

Maastricht UMC+

Maastricht, Limburg, 6229HX, Netherlands

RECRUITING

Related Publications (1)

• Henkens MTHM, Weerts J, Verdonschot JAJ, Raafs AG, Stroeks S, Sikking MA, Amin H, Mourmans SGJ, Geraeds CBG, Sanders-van Wijk S, Barandiaran Aizpurua A, Uszko-Lencer NHMK, Krapels IPC, Wolffs PFG, Brunner HG, van Leeuwen REW, Verhesen W, Schalla SM, van Stipdonk AWM, Knackstedt C, Li X, Abdul Hamid MA, van Paassen P, Hazebroek MR, Vernooy K, Brunner-La Rocca HP, van Empel VPM, Heymans SRB. Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. ESC Heart Fail. 2022 Apr;9(2):1463-1470. doi: 10.1002/ehf2.13833. Epub 2022 Feb 4.

  PMID: 35118823 BACKGROUND

Related Links

• Website with more information on the study

Biospecimen

Retention: SAMPLES WITH DNA

blood, urine, and cardiac biopsy samples

MeSH Terms

Conditions

Heart Failure; Cardiomyopathies; Atrial Fibrillation; Coronary Artery Disease; Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Coronary Disease; Myocardial Ischemia; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Tachycardia; Cardiac Conduction System Disease

Study Officials

• Hans-Peter Brunner-La Rocca, Prof.

  Maastricht University Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jerremy Weerts, MD

CONTACT

+ 31 43 3871592; jerremy.weerts@mumc.nl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 15 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 22, 2021
• First Posted: July 26, 2021
• Study Start: July 1, 2021
• Primary Completion (Estimated): December 1, 2051
• Study Completion (Estimated): December 1, 2051
• Last Updated: November 21, 2024

Record last verified: 2024-11

Locations

NL (1)